Pfizer Inc. (PFE)

53.01
0.47 0.89
NYSE
Prev Close 52.54
Open 52.57
Day Low/High 52.45 / 53.62
52 Wk Low/High 33.36 / 61.71
Volume 39.56M
Exchange NYSE
Shares Outstanding 5612.87B
Market Cap 289.29B
P/E Ratio 23.58
Div & Yield N.A. (N.A)

Latest News

Markets, Treasuries, Taxes, 2022 Expectations, FOMC, 2 Stocks to Watch

Markets, Treasuries, Taxes, 2022 Expectations, FOMC, 2 Stocks to Watch

Negative returns for 2022? It's a midterm election year. We will see increased volatility. Anything is possible, and it would not surprise me.

Markets, Data Dump, Student Loans, TikTok, Merck, Trading Salesforce

Markets, Data Dump, Student Loans, TikTok, Merck, Trading Salesforce

Friday might be a market holiday, but it became obvious on Wednesday that trading volumes had started to truly dwindle.

These 2 Undervalued Biotechs Are Ripe for Acquisition

These 2 Undervalued Biotechs Are Ripe for Acquisition

Mirum Pharmaceuticals and TG Therapeutics are undervalued as stand-alone entities, but also would make easy and logical targets for a larger player.

Omicron, Biden, Market Rally, Covid Fighting Pills, Trading Apple

Omicron, Biden, Market Rally, Covid Fighting Pills, Trading Apple

Perhaps the rally had been set up by the depth of the pressure placed on financial markets over the prior three days. Perhaps.

Pfizer Gets Chai!

Pfizer bets on medical cannabis.

Omicron Threat, Slowing Economic Activity, Week Ahead, 4 Trading Thoughts

Omicron Threat, Slowing Economic Activity, Week Ahead, 4 Trading Thoughts

Bear in mind that as Omicron threatens to, and will to some degree, slow economic activity, the real catalyst will be the political and policy response.

A 'Here We Go Again'-Kinda Day Winds Down

Markets ended mixed for the day as options expire. Pfizer continues to pick up bulls, it seems. Cantor Fitzgerald believes the company's Covid-19 vaccine and hotly anticipated antiviral drug could generate combined peak sales of between $50 billion ...

Can Biotech Keep This Up? Also, Unions a Tall Order for Starbucks?

Market has not moved much since our last update. Biotech continues to be one of the strongest sectors today with the SPDR S&P Biotech ETF  up nearly 5% on the day. It will be interesting to see if biotech can hold its gains into the close given it i...

Eye on Skyworks, a Potential Acquisition and Omicron

Looks like we are going to open the last day of what has been a miserable week for the markets in the red, based on where futures are currently trading. Small-caps, once again, look like they will take the brunt of the early decline. Skyworks Soluti...

We See Multiple Boosts Ahead for Pfizer

We See Multiple Boosts Ahead for Pfizer

We have new price targets for soaring shares of PFE. Let's check the charts.

The Bedraggled Biotech Sector Finally Offers a Glimmer of Hope

The Bedraggled Biotech Sector Finally Offers a Glimmer of Hope

Two recent acquisition deals and big drug companies that are flush with cash provide reason to believe biotech stocks could rebound in 2022

The Most (Mr.) Wonderful Time of the Year for Dividend Income

The Most (Mr.) Wonderful Time of the Year for Dividend Income

The top-10 holdings of Kevin O'Leary's O'Shares FTSE U.S. Quality Dividend ETF are an interesting source of quality dividend growth stocks.

No Ordinary Day, Trouble With the Curve, Crypto, Memes, Trading Pfizer, Nvidia

No Ordinary Day, Trouble With the Curve, Crypto, Memes, Trading Pfizer, Nvidia

The fact is that some blood hit the floor on Monday.

Lay of the Land, Central Bankers, Looking Ahead, ETFs, Inflation, Apple at 3T

Lay of the Land, Central Bankers, Looking Ahead, ETFs, Inflation, Apple at 3T

Yes, volatility beckons. I hear it too. There may be a revaluation of equities across the board in 2022.

Bitten Market, Waning Volume, Virus Thoughts, Jobless Claims Quirk, CPI Watch

Bitten Market, Waning Volume, Virus Thoughts, Jobless Claims Quirk, CPI Watch

Plus, a quick look at earnings report winners and losers from Thursday after the market closed.

Morale Boost, Searching for Correlation, Evergrande, CPI Watch, Trading UiPath

Morale Boost, Searching for Correlation, Evergrande, CPI Watch, Trading UiPath

I remain more comfortable trading than investing until there is at least one notably upward trading day on notably higher aggregate trading volume.

The Final 4 Bedraggled Stocks for My 2022 Tax Loss Selling Recovery Portfolio

The Final 4 Bedraggled Stocks for My 2022 Tax Loss Selling Recovery Portfolio

This quartet has had a rough 2021 but could be in for a rebound next year once investors harvest their losses in the shares.

From Despair to Euphoria in 10 Days: It's No Time to Chase

* The argument for holding above average levels of cash remains intact * I have no interest in chasing the recent market strength * The new regime of volatility in both bonds and stocks may augur poorly for financial asset prices over the next few m...

The Surge, Tech Plays, Trading Marvell and MongoDB, Debt Ceiling, Taxes, Omicron

The Surge, Tech Plays, Trading Marvell and MongoDB, Debt Ceiling, Taxes, Omicron

Plus, One must ask themselves... Are Russia and China satisfied with making Ukraine and Taiwan uncomfortable? Do they understand the costs?

SPY Add

On the Pfizer news, I have added to my short at $470.39.

This Market Is Just a Puppet on a String

This Market Is Just a Puppet on a String

Stick with energy stocks, and realize that in the current no-yield world stocks are bonds.

The Indexes Are Covering Up a Major Market Correction

The Indexes Are Covering Up a Major Market Correction

In the last 30 days, around 95% of stocks are down 25% or more, but the S&P 500 is down only 4%.

Should Investors Believe in Bounces as Markets Get Choppy?

Should Investors Believe in Bounces as Markets Get Choppy?

Sector selection will remain paramount as pandemic effects continue to permeate.

Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales

Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales

Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.

Why I Am Now Less Bearish

* While I am not bullish, I am less bearish * On a (tactical) trading and even on an investing basis, markets may have overreacted to the Omicron news on Friday * I covered a bunch of shorts on Friday * It might be time to consider being a bit more ...

Omicron, Black Friday, Jobs Week, Cybersecurity, Trading Zscaler

Omicron, Black Friday, Jobs Week, Cybersecurity, Trading Zscaler

I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.

With the Virus Still in Charge, Pfizer Can Be Flexible: Here's My Plan

With the Virus Still in Charge, Pfizer Can Be Flexible: Here's My Plan

PFE has created what appears to potentially be the most effective antiviral for those already infected.